m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05555
|
[1] | |||
m6A modification
hsa-miR-21-5p
hsa-miR-21-5p
METTL3
Methylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
miR-21-5p
SPRY1
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | hsa-miR-21-5p | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | hsa-miR-21-5p | microRNA | View Details | ||
| Regulated Target | Sprouty RTK signaling antagonist 1 (SPRY1) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | METTL3-m6A-miR-21-5p-Sprouty RTK signaling antagonist 1 (SPRY1)/ERK/NF-kB axis in obstructive renal fibrosis and provides a deeper understanding of renal fibrosis. | ||||
| Responsed Disease | Kidney disorders | ICD-11: GB90 | |||
| Pathway Response | NF-kappa B signaling pathway | hsa04064 | |||
| Cell Process | Inflammation | ||||
In-vitro Model |
HK-2 [Human kidney] | Normal | Homo sapiens | CVCL_0302 | |
| In-vivo Model | Each mouse was anaesthetized with inhaled isoflurane, and the left proximal ureter was exposed. Then, the ureter was ligated with 6-0 silk thread and severed. In the sham operation group, the left ureters of mice were exposed, but not ligated or severed. The 3rd, 7th and 14th days after surgery were the time points for killing. At each time point, a total of 10 mice in the UUO group were executed, and a total of 10 mice in the sham group were also executed to serve as controls. | ||||